117 related articles for article (PubMed ID: 12644115)
1. Preemptive therapy for the prevention of cytomegalovirus disease following heart transplantation directed by PP65 antigenemia.
Villa M; Lage E; Ballesteros S; Cañas E; Sánchez M; Ordóñez A; Borrego JM; Hinojosa R; Cisneros JM
Transplant Proc; 2003 Mar; 35(2):732-4. PubMed ID: 12644115
[No Abstract] [Full Text] [Related]
2. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
3. Clinical correlates of pp65 antigenemia monitoring in the first months of post kidney transplant in patients undergoing universal prophylaxis or preemptive therapy.
Carvalho FR; Cosendey RI; Souza CF; Medeiros T; Menezes PA; Silva AA; Almeida JR; Lugon JR
Braz J Infect Dis; 2017; 21(1):51-56. PubMed ID: 27888673
[TBL] [Abstract][Full Text] [Related]
4. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
[TBL] [Abstract][Full Text] [Related]
5. Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors.
Grossi P; Kusne S; Rinaldo C; St George K; Magnone M; Rakela J; Fung J; Starzl TE
Transplantation; 1996 Jun; 61(11):1659-60. PubMed ID: 8669117
[No Abstract] [Full Text] [Related]
6. Cytomegalovirus infection after liver transplantation using different prophylaxes.
Kornberg A; Grube T; Hommann M; Schotte U; Scheele J
Transplant Proc; 2001; 33(7-8):3624-5. PubMed ID: 11750539
[No Abstract] [Full Text] [Related]
7. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
Solano C; Muñoz I; Gutiérrez A; Farga A; Prósper F; García-Conde J; Navarro D; Gimeno C
J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients.
Potena L; Grigioni F; Magnani G; Lazzarotto T; Musuraca AC; Ortolani P; Coccolo F; Fallani F; Russo A; Branzi A
J Heart Lung Transplant; 2009 May; 28(5):461-7. PubMed ID: 19416774
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of pp65 antigenemia and viremia in the follow-up of renal transplant recipients with cytomegalovirus disease treated with ganciclovir.
Reina J; Ballesteros F; Gasco J; Munar M; Mari M
Diagn Microbiol Infect Dis; 2000 Jun; 37(2):83-6. PubMed ID: 10863101
[TBL] [Abstract][Full Text] [Related]
10. Use of cytomegalovirus antigenemia as a marker for preemptive treatment.
Guirado L; Herreros MA; Muñoz JM; Rabella N; Facundo C; Agraz I; Díaz M; Diaz JM; Durán F; Solà R
Transplant Proc; 2002 Feb; 34(1):67-8. PubMed ID: 11959188
[No Abstract] [Full Text] [Related]
11. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
[TBL] [Abstract][Full Text] [Related]
12. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
[TBL] [Abstract][Full Text] [Related]
13. Prevention of cytomegalovirus disease after heart transplantation: preemptive therapy with 7 days' intravenous ganciclovir.
Paniagua MJ; Crespo-Leiro MG; De la Fuente L; Tabuyo T; Mosquera I; Cañizares A; Naya C; Fariña P; Juffé A; Castro-Beiras A
Transplant Proc; 2002 Feb; 34(1):69-70. PubMed ID: 11959189
[No Abstract] [Full Text] [Related]
14. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].
Orlić P; Dvornik S; Husnjak SC; Aralica M; Orlić L; Zivcić-Cosić S; Sladoje-Martinović B; Fućak M
Acta Med Croatica; 2003; 57(1):49-52. PubMed ID: 12876863
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R
Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients.
Kusne S; Grossi P; Irish W; St George K; Rinaldo C; Rakela J; Fung J
Transplantation; 1999 Oct; 68(8):1125-31. PubMed ID: 10551640
[TBL] [Abstract][Full Text] [Related]
17. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Pajand O; Ziyaeyan M; Mousavi S; Fatolahzadeh B; Hojabri Z; Bahador A; Abdossamadi Z
Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
[TBL] [Abstract][Full Text] [Related]
19. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
[TBL] [Abstract][Full Text] [Related]
20. Cytomegalovirus reactivation and preemptive therapy after liver transplant.
Davoudi S; Kasraianfard A; Ahmadinejad Z; Najafi A; Salimi J; Makarem J; Sohrabpour AA; Jafarian A
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():72-5. PubMed ID: 24635797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
